CheckMate 025

a randomized, open-label, phase Ill study of nivolumab versus everolimus in advanced renal cell carcinoma (RCC)

Robert J. Motzer, Bernard Escudier, David F. Mcdermott, Saby George, Hans J. Hammers, Sandhya Srinivas, Scott S. Tykodi, Jeffrey A. Sosman, Giuseppe Procopio, Elizabeth R. Plimack, Daniel Castellano, Howard Gurney, Frede Donskov, Petri Bono, John Wagstaff, Thomas C. Gauler, Takeshi Ueda, Li-An Xu, Ian M. Waxman, Padmanee Sharma & 1 others CheckMate 025 Investigators

Research output: Contribution to journalMeeting abstract

12 Citations (Scopus)
Original languageEnglish
Pages (from-to)17
Number of pages1
JournalBJU international
Volume116
Issue numberS5
Publication statusPublished - Dec 2015
Externally publishedYes
Event14th International Kidney Cancer Symposium - Miami
Duration: 6 Nov 20157 Nov 2015

Cite this

Motzer, R. J., Escudier, B., Mcdermott, D. F., George, S., Hammers, H. J., Srinivas, S., ... CheckMate 025 Investigators (2015). CheckMate 025: a randomized, open-label, phase Ill study of nivolumab versus everolimus in advanced renal cell carcinoma (RCC). BJU international, 116(S5), 17.